Información del artículo
Abstract
Dermatomyositis is an idiopathic inflammatory myopathy that affects skeletal muscle and the skin. Idiopathic inflammatory myopathies are characterized by the production of autoantibodies directed against different cell structures. Some of these autoantibodies are specific to idiopathic inflammatory myopathies (myositis-specific antibodies) whereas others are found in a range of overlap syndromes (myositis-associated antibodies). Although they are all associated with certain clinical and physiopathological characteristics of myositis, myositis-specific antibodies are essentially the most useful markers for clinical diagnosis, classification, and prognosis in idiopathic inflammatory myopathies. In recent years, two new myositis-specific antibodies–-in clinically amyopathic dermatomyositis (CADM), CADM-140 and, in cancer-associated dermatomyositis, anti-p155/p140–-have been identified. This is of great importance as no myositis-specific antibodies had previously been detected in these clinical subgroups. The identification of target antigens that are recognized by these antibodies is essential for a better understanding of the pathogenesis of these diseases.
Key words:
idiopathic inflammatory myopathy
polymyositis
amyopathic dermatomyositis
cancer-associated dermatomyositis
myositis-specific antibodies
Resumen
La dermatomiositis es un tipo de miopatía inflamatoria idiopática que afecta al músculo esquelético y a la piel. Las miopatías inflamatorias idiopáticas se caracterizan por la producción de autoanticuerpos que se dirigen frente a diversas estructuras de la célula. Algunos de estos autoanticuerpos resultan específicos de las miopatías inflamatorias idiopáticas (anticuerpos específicos de miositis), mientras que otros se encuentran en diversos síndromes de solapamiento (anticuerpos asociados a miositis). Todos ellos determinan ciertas características clínicas y patofisiológicas de miositis, pero son principalmente los anticuerpos específicos de miositis los que constituyen marcadores muy útiles para el diagnóstico clínico, la clasificación y la predicción del pronóstico en las miopatías inflamatorias idiopáticas. En los últimos años se han identificado dos nuevos anticuerpos específicos de miositis, el anti-CADM-140 en la dermatomiositis amiopática y el anti-p155 y anti-p155/p140 en la dermatomiositis asociada a cáncer. Ello tiene una gran trascendencia ya que en estos subgrupos clínicos no se detectaban anticuerpos específicos de miositis. La identificación de los antígenos diana que reconocen estos anticuerpos resultará fundamental para comprender mejor la etiopatogenia de estas enfermedades.
Palabras clave:
miopatía inflamatoria idiopática
polimiositis
dermatomiositis amiopática
dermatomiositis asociada a cáncer
anticuerpos específicos de miositis
El Texto completo está disponible en PDF
References
[1.]
M.C. Dalakas.
Polymyositis, dermatomyositis and inclusion-body myositis.
N Engl J Med, 325 (1991), pp. 1487-1498
[2.]
F.W. Miller.
Classification and prognosis of inflammatory muscle disease.
Rheum Dis Clin North Am, 20 (1994), pp. 811-826
[3.]
A. Bohan, J.B. Peter.
Polymyositis and dermatomyositis: parts 1 and 2.
N Engl J Med, 292 (1975), pp. 344-347
[4.]
L.A. Love, R.L. Leff, D.D. Fraser, I.N. Targoff, M. Dalakas, P.H. Plotz, et al.
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Medicine (Baltimore), 70 (1991), pp. 360-374
[5.]
T. Mimori, Y. Imura, R. Nakashima, H. Yoshifugi.
Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance.
Curr Opin Rheumatol, 19 (2007), pp. 523-529
[6.]
I.N. Targoff.
Immune manifestations of inflammatory muscle disease.
Rheum Dis Clin North Am, 20 (1994), pp. 857-879
[7.]
Z. Betteridge, H. Gunawardena, J. North, J. Slinn, N. McHugh.
Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia.
Rheumatology (Oxford), 46 (2007), pp. 1005-1008
[8.]
L. Hashish, E.P. Tribu, P. Sadanandan, I.N. Targoff.
Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (abstract).
Arthritis Rheum, 52 (2005), pp. S312
[9.]
A. Imbert-Masseau, M. Hamidou, C. Agard, J.Y. Grolleau, P. Chérin.
Antisynthetase syndrome.
Joint Bone Spine, 70 (2003), pp. 161-168
[10.]
H. Yoshifuji, T. Fujii, S. Kobayashi, Y. Imura, Y. Fujita, D. Kawabata, et al.
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
Autoimmunity, 39 (2006), pp. 233-241
[11.]
N.L. Stahl, J.H. Klippel, J.L. Decker.
A cutaneous lesion associated with myositis.
Ann Intern Med, 91 (1979), pp. 577-579
[12.]
D. Mitra, C.L. Lovell, T.IF. Macleod, R.SH. Tan, P.J. Maddison.
Clinical and histological features of «mechanic's hands» in a patient with antibodies to Jo-1. A case report.
Clin Exp Dermatol, 19 (1994), pp. 146-148
[13.]
F. Indart, A. España, M.A. Idoate, I. Lucas, E. Quintanilla.
A cutaneous lesion associated with primary polymyositis.
Arch Dermatol, 129 (1993), pp. 1207-1208
[14.]
V. García-Patos, R. Bartralot, V. Fonollosa, C. Arnal, M. Boronat, C. Gelpí, et al.
Childhood sclerodermatomyositis: report of a case with the anti-PM/Scl antibody and mechanic's hands.
Br J Dermatol, 135 (1996), pp. 613-616
[15.]
I.N. Targoff, M. Reichlin.
The association between Mi-2 antibodies and dermatomyositis.
Arthritis Rheum, 28 (1985), pp. 796-803
[16.]
H.P. Seelig, I. Moosbrugger, H. Ehrfeld, T. Fink, M. Renz, E. Genth.
The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation.
Arthritis Rheum, 38 (1995), pp. 1389-1399
[17.]
Q. Ge, D.S. Nilasena, C.A. O’Brien, M.B. Frank, I.N. Targoff.
Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen.
J Clin Invest, 96 (1995), pp. 1730-1737
[18.]
H.P. Seelig, M. Renz, I.N. Targoff, Q. Ge, M.B. Frank.
Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen.
Arthritis Rheum, 39 (1996), pp. 1769-1771
[19.]
G.J. Hengstman, W.T. Vree Egberts, H.P. Seelig, I.E. Lundberg, H.M. Moutsopoulos, A. Doria, et al.
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.
Ann Rheum Dis, 65 (2006), pp. 242-245
[20.]
I.N. Targoff, A.E. Johnson, F.W. Miller.
Antibody to signal recognition particle in polymyositis.
Arthritis Rheum, 33 (1990), pp. 1361-1370
[21.]
M. Hirakata, T. Mimori, M. Akizuki, J. Craft, J.A. Hardin, M. Homma.
Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease.
Arthritis Rheum, 35 (1992), pp. 449-456
[22.]
G.J. Hengstman, H.J. Ter Laak, W.T. Vree Egberts, I.E. Lundberg, H.M. Moutsopoulos, J. Vencovsky, et al.
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.
Ann Rheum Dis, 65 (2006), pp. 1635-1638
[23.]
J.B. Arlet, D. Dimitri, C. Pagnoux, O. Boyer, T. Maisonobe, F.J. Authier, et al.
Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).
Neuromuscul Disord, 16 (2006), pp. 334-336
[24.]
P. Gerami, J.M. Schope, L. McDonald, H.W. Walling, R.D. Sontheimer.
A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
J Am Acad Dermatol, 54 (2006), pp. 597-613
[25.]
R.D. Sontheimer.
Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis.
Curr Opin Rheumatol, 11 (1999), pp. 475-482
[26.]
R.L. Euwer, R.D. Sontheimer.
Amyopathic dermatomyositis: a review.
J Invest Dermatol, 100 (1993), pp. 124S-127S
[28.]
M.R. Stonecipher, J.L. Jorizzo, J. Monu, F. Walker, P.G. Sutej.
Dermatomyositis with normal muscle enzyme concentrations. A single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound.
Arch Dermatol, 130 (1994), pp. 1294-1299
[29.]
A. Cosnes, F. Amaudric, R. Gherardi, J. Verroust, J. Wechsler, J. Revuz, et al.
Dermatomyositis without muscle weakness. Long term follow-up of 12 patients without systemic corticosteroids.
Arch Dermatol, 131 (1995), pp. 1381-1385
[30.]
S. Sato, M. Hirakata, M. Kuwana, A. Suwa, S. Inada, T. Mimori, et al.
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.
Arthritis Rheum, 52 (2005), pp. 1571-1576
[31.]
R.L. Euwer, R.D. Sontheimer.
Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature.
J Am Acad Dermatol, 24 (1991), pp. 959-966
[32.]
R.A. El-Azhary, S.Y. Pakzad.
Amyopathic dermatomyositis: Retrospective review of 37 cases.
J Am Acad Dermatol, 46 (2002), pp. 560-565
[33.]
M. Caproni, C. Cardinali, A. Parodi, B. Giomi, M. Papini, M. Vaccaro, et al.
Amyopathic dermatomyositis: a review by the Italian group of immunodermatology.
Arch Dermatol, 138 (2002), pp. 23-27
[34.]
L.A. Manchul, A. Jin, K.I. Pritchard, J. Tenenbaum, N.F. Boyd, P. Lee, et al.
The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study.
Arch Intern Med, 145 (1985), pp. 1835-1839
[35.]
S. Lakhanpal, T.W. Bunch, D.M. Ilstrup, L.J. Melton 3rd.
Polymyositis-dermatomyositis and malignant lesions: does an association exist?.
Mayo Clin Proc, 61 (1986), pp. 645-653
[36.]
M.G. Lyon, D.A. Bloch, B. Hollak, J.F. Fries.
Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey.
J Rheumatol, 16 (1989), pp. 1218-1224
[37.]
B. Sigurgeirsson, B. Lindelöf, O. Edhag, E. Allander.
Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.
N Engl J Med, 326 (1992), pp. 363-367
[38.]
W.H. Chow, G. Gridley, L. Mellemkjaer, J.K. McLaughlin, J.H. Olsen, J.F. Fraumeni Jr.
Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.
Cancer Causes Control, 6 (1995), pp. 9-13
[39.]
A. Airio, E. Pukkala, H. Isomäki.
Elevated cancer incidence in patients with dermatomyositis: a population based study.
J Rheumatol, 22 (1995), pp. 1300-1303
[40.]
C.R. Maoz, P. Langevitz, A. Livneh, Z. Blumstein, M. Sadeh, I. Bank, et al.
High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis.
Semin Arthritis Rheum, 27 (1998), pp. 319-324
[41.]
M. Patrick, R. Buchbinder, D. Jolley, X. Dennett, R. Buchanan.
Incidence of inflammatory myopathies in Victoria, Australia,and evidence of spatial clustering.
J Rheumatol, 26 (1999), pp. 1094-1100
[42.]
R. Buchbinder, A. Forbes, S. Hall, X. Dennett, G. Giles.
Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study.
Ann Intern Med, 134 (2001), pp. 1087-1095
[43.]
C.L. Hill, Y. Zhang, B. Sigurgeirsson, E. Pukkale, L. Mellemkjaer, A. Airio, et al.
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.
Lancet, 357 (2001), pp. 96-100
[44.]
J. Benbassat, D. Gefel, K. Larholt, S. Sukenik, V. Morgenstern, A. Zlotnick.
Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases.
Arthritis Rheum, 28 (1985), pp. 249-255
[45.]
N.H. Cox, C.M. Lawrence, J.A. Langtry, F.A. Ive.
Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy.
Arch Dermatol, 12 (1990), pp. 61-65
[46.]
I. Marie, P.Y. Hatron, H. Levesque, E. Hachulla, M.F. Hellot, U. Michon-Pasturel, et al.
Influence of age on characteristics of polymyositis and dermatomyositis in adults.
Medicine (Baltimore), 78 (1999), pp. 139-147
[47.]
E. Pautas, P. Chérin, J.C. Piette, S. Pelletier, B. Wechsler, J. Cabane, et al.
Features of polymyositis and dermatomyositis in the elderly: a case-control study.
Clin Exp Rheumatol, 18 (2000), pp. 241-244
[48.]
Y.J. Chen, C.Y. Wu, J.L. Shen.
Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.
Br J Dermatol, 144 (2001), pp. 825-831
[49.]
J.P. Callen.
Dermatomyositis.
Lancet, 355 (2000), pp. 53-57
[50.]
N. Basset-Seguin, J.C. Roujeau, R. Gherardi, J.C. Guillaume, J. Revuz, R. Touraine.
Prognosis factors and predictive signs of malignancy in adult dermatomyositis.
Arch Dermatol, 126 (1990), pp. 633-637
[51.]
V. Gallais, B. Crickx, S. Belaïch.
Facteurs pronostiques et signes prédictifs de cancer au cours de la dermatomyosite de l’adulte.
Ann Dermatol Venereol, 123 (1996), pp. 722-726
[52.]
M. Burnouf, E. Mahé, P. Verpillat, V. Descamps, B. Lebrun-Vignes, C. Picard-Dahan, et al.
Les nécroses cutanées dans les dermatomyosites de l’adulte sont prédictives de l’association à une néoplasie.
Ann Dermatol Venereol, (2003), pp. 313-316
[53.]
J.M. Grau, O. Miró, E. Pedrol, J. Casademont, F. Masanés, C. Herrero, et al.
Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement.
J Rheumatol, 23 (1996), pp. 1921-1926
[54.]
Z. Amoura, P. Duhaut, D.L. Huong, B. Wechsler, N. Costedoat-Chalumeau, C. Francès, et al.
Tumor antigen markers for the detection of solid cancers in inflammatory myopathies.
Cancer Epidemiol Biomarkers Prev, 14 (2005), pp. 1279-1282
[55.]
E.J. Fudman, T.J. Schnitzer.
Dermatomyositis without creatine kinase elevation. A poor prognostic sign.
Am J Med, 80 (1986), pp. 329-332
[56.]
S.E. Whitmore, R. Watson, N.B. Rosenshein, T.T. Provost.
Dermatomyositis sine myositis: association with malignancy.
J Rheumatol, 23 (1996), pp. 101-105
[57.]
W.K. Fung, H.L. Chan, W.M. Lam.
Amyopathic dermatomyositis in Hong Kong: association with nasopharyngeal carcinoma.
Int J Dermatol, 37 (1998), pp. 659-663
[58.]
A. Sparsa, E. Liozon, F. Herrmann, K. Ly, V. Lebrun, P. Soria, et al.
Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients.
Arch Dermatol, 138 (2002), pp. 885-890
[59.]
G. La Montagna, C. Manzo, E. Califano, R. Tirri.
Absence of elevated creatine kinase in dermatomyositis does not exclude malignancy.
Scand J Rheumatol, 17 (1988), pp. 73-74
[60.]
Y. Troyanov, I.N. Targoff, J.L. Tremblay, J.R. Goulet, Y. Raymond, J.L. Senécal.
Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.
Medicine (Baltimore), 84 (2005), pp. 231-249
[61.]
I.N. Targoff, R.D. Sontheimer.
Autoantibodies to 155 kD and Se autoantigens in patients with clinically-amyopathic dermatomyositis.
Arthritis Rheum, 43 (2000), pp. S194
[62.]
I.N. Targoff, G. Mamyrova, E.P. Trieu, O. Perurena, B. Koneru, T.P. O’Hanlon, et al.
A novel autoantibody to a 155-kd protein is associated with dermatomyositis.
Arthritis Rheum, 54 (2006), pp. 3682-3689
[63.]
I.N. Targoff, E.P. Trieu, M. Levy-Neto, F.W. Miller.
Autoantibodies to transcriptional intermediary factor-1 gamma (TIF-1y) in dermatomyositis (abstract).
Arthritis Rheum, 54 (2006), pp. S518
[64.]
K. Kaji, M. Fujimoto, M. Hasegawa, M. Kondo, Y. Saito, K. Komura, et al.
Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Rheumatology (Oxford), 46 (2007), pp. 25-28
[65.]
H. Chinoy, N. Fertig, C.V. Oddis, W.E. Ollier, R.G. Cooper.
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Ann Rheum Dis, 66 (2007), pp. 1345-1349
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
